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Summary: Intraduodenal (i.d.) application of bile or Na- 
taurodeoxycholate (TDC) dose dependently enhances 
basal exocrine pancreatic secretion. The hydrokinetic ef- 
fect is mediated at least in part by secretin. This study 
should show, whether vasoactive intestinal polypeptide 
(VIP), a partial agonist of secretin, may also be involved 
in the mediation of the hydrokinetic effect. Furthermore, 
plasma concentrations of somatostatin-like immunoreac- 
tivity (SLI) were measured in order to check whether this 
counterregulating hormone is also released by bile and 
TDC. Twenty investigations were carried out on 10 fast- 
ing healthy volunteers provided with a double-lumen 
Dreiling tube. Bile and TDC were intraduodenally applied 
in doses of 2-6 g and 200-600 mg, respectively, at 65-min 
intervals. Plasma samples were withdrawn at defined in- 
tervals for radioimmunological determination of VIP and 
SLI. Duodenal juice was collected in 10-min fractions and 
analyzed for volume, pH, bicarbonate, lipase, trypsin, 
and amylase. 1.d. application of bile or TDC dose depen- 
dently stimulated hydrokinetic and ecbolic pancreatic se- 
cretion. Bile exerted a slightly stronger effect than TDC. 
Pancreatic response was simultaneously accompanied by 
a significant increase of plasma VIP and SLI concentra- 
tions. The effect of bile on integrated plasma VIP and SLI 
concentrations seems to be dose dependent; the effect of 
TDC on integrated SLI, too. For the increase of inte- 
grated plasma VIP concentrations after TDC no dose- 
response relation could be established. We conclude that 
VIP may be a further mediator of bile-induced volume 
and bicarbonate secretion. The release of plasma SLI in- 
dicates that inhibitory mechanisms concomitantly are 
triggered by i.d. bile and TDC, as already shown during 
digestion for the intestinal phase of pancreatic secretion. 
Key Words: Bile-Duodenum-Pancreatic secretion- 
Somatostatin-Taurodeoxycholate-Vasoactive intesti- 
nal polypeptide. 
Intraduodenal (i.d.) application of bile or Na- 
taurodeoxycholate (TDC) dose dependently en- 
hances basal (1) and secretin-stimulated (2) hydro- 
kinetic and ecbolic pancreatic secretion in man. The 
pancreatic response to i.d. bile (1,3,4) or bile salts 
(1,5,6) is accompanied by a release of secretin, the 
most important hormonal mediator of pancreatic 
volume and bicarbonate secretion (7-9). 
Vasoactive intestinal polypeptide (VIP) acts as a 
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weak hydrokinetic stimulus (10) in man. Burhol et 
al. (11) were able to show in man, that i.d. applica- 
tion of bile induces an increase of pancreatic hydro- 
kinetic function and a release of VIP as well. In this 
investigation, however, only a single, high dose (6 
g) of bile was applied. Moreover, Chayvialle et al. 
(12) were not able to demonstrate a release of VIP 
in both portal and peripheral plasma after i.d. bile (3 
g) in dogs. Therefore, one purpose of the present 
study was to investigate in man, whether VIP is 
dose dependently released by physiological loads of 
bile or TDC, a very effective bile salt with regard to 
pancreatic secretion (2). 
The intestinal phase of pancreatic secretion rep- 
resents a net sum resulting from the responses to 
stimulatory and inhibitory mechanisms, as well 
(13). As we previously showed in man (l), i.d. ap- 
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plication of bile or TDC dose dependently increases 
the plasma levels of pancreatic polypeptide (PP), an 
inhibitor of pancreatic secretion (14). In dogs, 
Chayvialle et al. (12) observed a bile-induced re- 
lease of somatostatin, a potent inhibitor of exocrine 
pancreatic function (15,16). On the contrary, 
Burhol et al. (17) did not find an augmentation of 
plasma somatostatin by bile in man. Therefore, an- 
other aim of our study was to reexamine the influ- 
ence of bile and TDC on the release of somatostat- 
in-like immunoreactivity (SLI) in man. 
METHODS 
Experimental procedure 
Twenty experiments were carried out on 10 fast- 
ing young healthy subjects. Full written consent 
was obtained from each subject, and the research 
protocol was approved by the Ethics Committee at 
the Medical Faculty. 
A double-lumen Dreiling tube was advanced to 
the ligament of Treitz under fluoroscopic control 
enabling continuous and separate aspiration of gas- 
tric and duodenal juice. Details have been described 
elsewhere (1,2). On one day, standardized dried 
cattle bile (kindly supplied by Kali-Chemie, Han- 
nover, FRG), dissolved in 20 ml H,O, was applied 
i.d. in doses of 2 (twice), 4, and 6 g (310, 639, and 
937 mosmol/L; pH 7.45, 7.18, and 7.04, respec- 
tively) at 65-min intervals. On another day, chro- 
matographically pure TDC (Calbiochem-Behring, 
FRG), again dissolved in 20 ml H,O, was used in 
doses of 200 (twice), 400, and 600 mg (19.0, 38.5, 
and 57.5 mmollL corresponding to 33.0, 50.0, and 
67.0 mosmol/L; pH 7.9, 8.1, and 8.1, respectively). 
The first stimulus in each series-2 g bile or 200 mg 
TDC, respectively-was given in order to "wash 
out" preformed zymogens from the pancreatic 
ducts. 
The bile preparation used in this study contained 
10% TDC based on weight. In order to compare the 
effects of total bile and TDC, respectively, doses of 
TDC were administered corresponding to the 
amounts applied with bile (e.g., 2 g bile contain 200 
mg TDC). Duodenal juice was collected in 10-min 
fractions and analyzed for volume, pH, bicarbon- 
ate, lipase, trypsin, and amylase. The pH values of 
the duodenal aspirate were within the neutral range 
after all i.d. stimuli. The determination of pancre- 
atic enzymes and bicarbonate was performed ac- 
cording to the recommendation of the Multi-Centre- 
Study of the European Pancreatic Club (18). Blood 
samples for radioimmunological determination of 
VIP and SLI were drawn from a peripheral vein in 
ice-chilled 10-ml syringes (containing 37.1 pmol K2- 
ethylenediaminetetraacetic acid (EDTA) and 5000 
KIU aprotinin) before, at, and 5 ,  10, 15,25,45, and 
65 min after i.d. application of bile or TDC. The 
samples were immediately centrifuged at 4"C, the 
plasma stored at - 20°C. 
Radioimmunoassay procedures 
Before the assays plasma samples were extracted 
with acetone. The supernatant was decanted and 
dried in a vacuum centrifuge (SpeedVac). The dried 
product was reconstructed to the original volume 
with assay buffer containing 0.1 M sodium citrate 
buffer (pH 6.5), 0.07 mmoYL bovine serum albu- 
min, 3.08 mmol/L NaN,, 500 KIUlml aprotinin, and 
50 pl/L polyoxyethylenesorbitan monolaurate 
(Tween 20). 
VIP 
Our VIP-antiserum (VI2X, K,, = 1.0 x 10" 
L/mol) showed no cross-reactivity with V1P1-12, 
other peptides of the secretin-glucagon family, and 
somatostatin-14. ['251]VIP (81.4 MBq/nmol; NEN, 
Dreieich, FRG) was used as tracer. The standard 
(400 pl, synthetic VIP; Sigma, Munich, FRG) and 
the sample (400 1.1) were incubated with 100 pl of a 
VIP antiserum/anti-rabbit y-globulin antiserum pre- 
cipitate (dilution of VIP antiserum 1:54,000), and 
100 ~1 of the tracer ("1 fmol) in assay buffer. After 
96 h in incubation bound and free label were sepa- 
rated by centrifugation at 4"C, the supernatant re- 
moved by suction, and the precipitate counted in an 
automatic y-counter as described previously (1). 
The detection limit of the assay was 1 pmol/L with 
95% confidence limit. Recovery of known amounts 
of VIP (3.9,7.1, and 35.4 pmol/L) in human plasma 
was 50 2 3% (tt & SD) at each concentration. The 
coefficient of variation for the within-assay preci- 
sion was 13.3, 13.4, and 9.9% at 3.0, 15.7, and 51.3 
pmol/L, respectively, and for the between-assay 
precision 15.3 and 13.9% at 12.4 and 27.4 pmol/L, 
respectively. 
Somatostatin 
Our antiserum against somatostatin-14 (S04VII1, 
KeE 1.1 x 10" L/mol) showed a cross-reactivity of 
80% with somatostatin-28 and none with gastrin- 
17(I), gastrin-34(1), sulfated cholecystokinin 
(CCK)-8 and CCK-33, peptides of the secretin- 
glucagon family, PP, peptide YY (PYY), and neu- 
ropeptide Y (NPY). ['251]-Tyr,-somatostatin-14 
(81.4 MBqhmol; NEN, Dreieich, FRG) was used 
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as tracer. The standard (300 pl, synthetic somato- 
statin-14; Sigma, Munich, FRG) and the sample 
(300 p1) were incubated with 100 p1 of a somatostat- 
in antiserum/anti-rabbit y-globulin antiserum pre- 
cipitate (dilution of somatostatin antiserum 
1:280,000), and 100 pl of the tracer (=l fmol) in 
assay buffer. Incubation and separation procedures 
were identical to those of VIP. The detection limit 
of the assay was 1 pmol/L with 95% confidence 
limit. Recovery of synthetic somatostatin-I4 (2.6, 
11.5, and 56.9 pmoYL) in human plasma was 57 t 
4% (X ? SD) at each concentration. The intra-assay 
coefficient of variation was 14.8 and 7.8% at 2.7 and 
15.4 pmoYL, respectively; the interassay coefficient 
of variation was 11.1 and 7% at 12.6 and 64.1 pmoY 
L, respectively. 
Gel chromatography studies showed that VIP im- 
munoreactivity in extracted plasma, synthetic VIP, 
and [‘251]-VIP eluted at identical positions. After 
i.d. application of 6 g bile, somatostatin-like immu- 
noreactivity in extracted plasma is eluted at two 
peaks corresponding to somatostatin-14 and so- 
matostatin-28 (40 and 60% of total SLI, respec- 
tively). Because of this heterogeneity the term so- 
matostatin-like immunoreactivity is used. 
Statistical methods 
All data were evaluated by the Friedman two- 
way analysis of variance; I, s 0.05 was considered 
statistically significant. The value before the second 
application of 2 g bile or 200 mg TDC, respectively, 
was used as “basal.” It proved to be statistically 
not different from the other prestimulatory values. 
In all figures values are presented as X * SEM. 
Integrated VIP and SLI values were calculated as 
the areas under the concentration curves for 10 min 
after application of each i.d. stimulus. 
RESULTS 
Plasma VIP concentrations significantly in- 
creased after all doses of bile and after 200 and 600 
mg of TDC (Figs. 1 and 2, top). Integrated plasma 
VIP was significantly enhanced by 4 and 6 g of bile 
and by 200 mg of TDC (Fig. 3, top). Integrated VIP 
was significantly higher after 6 g of bile as compared 
with 2 and 4 g. 
Plasma SLI concentrations were significantly 
raised by all doses of bile and TDC (Figs. 1 and 2, 
bottom). Integrated SLI significantly and dose de- 
pendently rose after all doses of bile and after 200 
and 400 mg of TDC; after 600 mg of TDC no further 
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FIG. 1. Effect of 2 ,2 ,4 ,  and 6 g of bile in the duodenum on the 
kinetics of plasma VIP (top) and SLI (bottom) concentrations (n 
= 10). A single asterisk indicates p S 0.05 and two asterisks p s 
0.01 compared with the basal value preceding the second i.d. 
stimulus (also in Figs. 2-5). 
increase of SLI was observed as compared with 400 
mg (Fig. 3, bottom). 
Parallel to the peptide release, volume, bicarbon- 
ate, lipase, trypsin, and amylase secretion signifi- 
cantly increased after 4 and 6 g bile and after all 
doses of TDC (Fig. 4; Table 1). After 2 g bile the 
increase was significant only for lipase. Volume se- 
cretion and bicarbonate output showed a dose- 
dependent augmentation after both i.d. stimuli, 
whereas enzyme output did not further increase af- 
ter the highest dose of bile and TDC, respectively 
(Fig. 5 ;  Table 1). Comparing the hydrokinetic and 
ecbolic effect of bile and TDC, a tendency to higher 
values was found after bile, reaching significance, 
however, only for bicarbonate after the respective 
highest dose (Fig. 4; Table 1). 
DISCUSSION 
The present study shows, that i.d. application of 
bile or TDC enhances plasma VIP and SLI levels 
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FIG. 2. Effect of 200, 200, 400, and 600 mg of TDC in the 
duodenum on the kinetics of plasma VIP (top) and SLI (bottom) 
concentrations (n = 10). 
simultaneously with an increase of hydrokinetic and 
ecbolic pancreatic secretion. 
The results are in accordance with our previous 
findings (1,2) that physiologic amounts of i.d. bile 
and TDC dose dependently stimulate volume, bi- 
carbonate, lipase, trypsin, and amylase secretion in 
man (Figs. 4, 5; Table 1). The applied bile solution 
contained 10% TDC. In order to compare the ef- 
fects of total bile and TDC, respectively, corre- 
sponding amounts of this bile salt were used. On 
this basis, TDC showed a slightly lower pancreatic 
response as compared with bile, reaching signifi- 
cance, however, only for bicarbonate after 600 mg 
TDC vs. 6 g bile. This observation is in agreement 
with another study showing that the effect of TDC 
can further be enhanced by combination with other 
bile salts (19). 
The stimulatory effect of bile salts does not de- 
pend on their action as detergents (20) or their acid- 
ity (21). Moreover, the pH of the solutions applied 
was kept neutral or slightly alkaline to exclude stim- 
ulation of pancreatic secretion by acid equivalents. 
Furthermore, the osmolality of the applied solu- 
tions cannot account for the stimulatory effect of 
bile and TDC, because i.d. infusion of a 20% solu- 
tion of mannitol (1,097 mosmol/kg) in man caused 
only a slight enhancement of volume secretion but 
exerted no effect on bicarbonate and enzyme output 
(22). Others (23,24) found no or even an inhibitory 
effect on pancreatic secretion by raising the osmo- 
lality of i.d. applied solutions in dogs. 
The method of repeated stimulus application was 
chosen, because intraindividual responses in exper- 
iments on different days vary considerably. Inter- 
vals of 65 min between stimulus applications were 
established to allow pancreatic secretion and pep- 
tide concentrations to return to prestimulatory val- 
ues. 
Previously, Burhol et al. (11) were able to dem- 
onstrate an increase of plasma VIP concentrations 
after i.d. application of a single dose of 6 g bile in 
man. Our data confirm this observation and show 
that 2 and 4 g i.d. bile also significantly enhance 
plasma VIP concentrations (Fig. 1) .  Furthermore, 
integrated plasma VIP was significantly higher after 
6 g bile as compared with 2 and 4 g bile, probably 
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FIG. 3. Dose-response plot of i.d. bile (left) and TDC (right) on 
integrated plasma VIP (top) and SLI (bottom) (n = 10). 
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FIG. 4. Effect of 2, 2 ,4 ,  and 6 g of bile (C-.) and of 200, 200, 
400, and 600 mg of TDC (.---a) on pancreatic bicarbonate (top) 
and lipase (bottom) secretion rate (n = 10). Lipase is represen- 
tative for all enzymes measured. 
indicating a dose-response relation (Fig. 3). An en- 
hancement of VIP levels secondary to an acid re- 
lease into the duodenum (25) was prevented by con- 
tinuous aspiration of gastric juice and documented 
by the neutral pH of the duodenal aspirate. Further- 
more, it is unlikely that the osmolality of the bile 
solutions is responsible for the VIP release, since 
Schaffalitzky de Muckadell et al. (25) found no in- 
BICARBONATE ,, (rnrnoi/lO min) BICARBONATE (mrnol/tO min) 
T 1 T 
"i 4 I* rt  :t 
113 
1 
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LlPASE 
(kU/l-hin) 
bile i d  
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(kU/l Omin) 
** 
- .  . 
basal 200 4 0  6 b m q  
TDC i.d. 
FIG. 5 .  Dose-response plot of i.d. bile (left) and TDC (right) on 
pancreatic bicarbonate (top) and lipase (bottom) output (n = 10). 
crease of peripheral VIP levels by i.d. perfusion 
with hypertonic glucose solutions in humans and 
hypertonic saline and glucose solutions in pigs. 
Thus, a nonspecific effect of bile may be ruled out. 
In contrast to the results in man, Chayvialle et al. 
(12) noted no change in systemic and only an insig- 
nificant rise in portal plasma VIP concentrations 
after i.d. application of 3 g bile in dogs. This dis- 
crepancy may be due to species differences and/or 
the different study design (26). In the latter experi- 
TABLE 1. Effect of i .d. bile and TDC on volume and bicarbonate secretion and on lipase, trypsin, and amylase 
output (n = 
Bile (9) TDC (mg) 
Basal 2 4 6 Basal 200 400 600 
Volume 
Bicarbonate 
Lipase 
Trypsin 
Amylase 
(mV10 min) 18.2 i 3.5 33.8 f 5.5 63.4 ? 5.3** 83.2 * 6.0** 10.3 k 1.4 32.7 f 4.7* 41.2 t 6.3** 61 f 9.3** 
(mmoY10 min) 0.6 i 0.2 0.9 t 0.2 2.9 C 0.7** 4.7 f 0.8** 0.3 f 0.1 0.7 f 0.2* 1.8 t 0.3** 2.3 t 0.5** 
(kUI10 min) 12.7 * 4.1 20.9 f 4.6* 37.7 -c 3.9** 38.9 t 3.3** 6.6 f 1.5 15.2 f 2.0* 33.2 t 5.1** 30.5 2 5.6** 
(kU/IO min) 0.6 f 0.2 1.2 t 0.2 2.6 C 0.4** 2.3 k 0.2** 0.2 k 0.9 1 .1  f 0.3* 2.2 f 0.4** 1.9 k 0.4** 
(kUI10 min) 4.2 f 1.5 9.1 i 2.6 12.2 -c 2.4** 12.2 k 1.9** 2.8 f 0.8 5.6 IT I.]* 9.9 2 2.3* 10.6 * 2.5* 
a A single asterisk indicates p s 0.05 and two asterisks p 5 0.01 compared with the basal value. 
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ments, pancreatic juice was not withdrawn from the 
duodenum. 
TDC, i.d. applied in a physiological dose range, 
significantly enhanced plasma VIP levels (Fig. 2). 
Integrated plasma VIP, however, increased signifi- 
cantly only after 200 mg of TDC and showed no 
further increase even at the highest dose of TDC 
used. As VIP was measured in peripheral, not in 
portal plasma, peaks of VIP release were only small 
and short lasting. Therefore, intraindividual varia- 
tions might have contributed to the missing dose 
dependence. 
VIP resembles secretin in its primary structure 
and its ability to stimulate pancreatic volume and 
bicarbonate secretion (27). VIP is a secretin-like full 
agonist in cats (27,28), but only a partial agonist in 
dogs (29), pigs (30), and man (31). The low potency 
of VIP [ I-5% as effective as secretin (32)] has been 
used as an argument against an important physio- 
logical role of VIP as a hormonal stimulant of hy- 
drokinetic pancreatic secretion. Because the exis- 
tence of VIP-containing endocrine cells of the gut is 
questioned as well (33), a hormonal action of VIP 
on the exocrine pancreas is uncertain. 
VIP is, however, now generally accepted as a 
peptidergic neurotransmitter (34,35). This regula- 
tory peptide is localized in vagal nerve fiber endings 
and in a dense network of peptidergic nerves in the 
pancreas (36-38). Moreover, VIP-ergic nerves 
travel along pancreatic ducts capable of water and 
bicarbonate secretion (39). Electrical stimulation of 
the vagus nerve in the isolated perfused pig pan- 
creas induces an atropine-resistent enhancement of 
pancreatic volume and bicarbonate secretion and a 
release of VIP into the portal effluent as well (39- 
41). 
As VIP is known to be rapidly degraded (34) and 
extracted from portal blood by the liver (42), only a 
small fraction escapes to the peripheral venous 
blood. Consequently, the increase of VIP in periph- 
eral plasma after i.d. bile or TDC apparently corre- 
sponds to higher VIP concentrations in the portal 
vein. Moreover, at the site of VIP release, i.e., the 
synaptic cleft between the VIP-ergic nerve termi- 
nals and the receptors in the pancreas, sufficiently 
high concentrations of VIP have to be assumed to 
be able to stimulate water and bicarbonate secretion 
(40). Therefore, an increase of VIP measured in pe- 
ripheral plasma may be an expression of an “over- 
spill” phenomenon of VIP from the synaptic cleft 
into the venous effluent. 
It cannot be excluded, that the bile-induced in- 
crease of plasma VIP partially originates from VIP- 
ergic neurons of the myenteric and submucous 
plexus of the duodenum or upper jejunum. Such a 
release, however, seems unlikely because very high 
amounts of bile (10.8 g) applied into the ileum of 
dogs did not influence peripheral plasma VIP levels 
(43) * 
Thus, neuronally released VIP may contribute to 
the mediation of pancreatic volume and bicarbonate 
secretion induced by i.d. bile or TDC, although VIP 
is considered merely as a partial agonist of secretin 
in man. 
Ingestion of a meal evokes not only stimulatory 
but also inhibitory mechanisms (13), probably to 
prevent an “overstimulation” of the effector organs 
(e.g., pancreas) (16,44). Previously, we found a 
dose-dependent increase of plasma PP levels after 
i.d. application of bile or TDC (1). The present 
study shows, that somatostatin is also released 
(Figs. 1-3). There was observed not only a signifi- 
cant increase of plasma SLI concentrations, but 
also a dose-dependent augmentation of integrated 
SLI after bile and 200 and 400 mg of TDC. An acid- 
induced rise of SLI (17) can be excluded (see 
above). In contrast, Burhol et al. (17) did not find a 
significant change of plasma SL1 after duodenal in- 
fusion of 3 g cattle bile in man. The reason for this 
discrepancy remains unclear. On the other hand, 
Chayvialle et al. (12) noted a significant increase of 
SLI in portal and peripheral plasma after i.d. appli- 
cation of 3 g bile in dogs. Gel chromatographic anal- 
ysis of plasma SLI released by bile revealed that 
total SLI consists of approximately 60% somato- 
statin-28 and 40% somatostatin-14. The release of 
somatostatin-28 may primarily be due to a direct 
action of bile on the duodenal D cells, because so- 
matostatin-28 is predominantly released from the 
proximal segment of the small intestine (45,46). So- 
matostatin- 14 is believed to originate from the stom- 
ach and the pancreas (45,46). Because in our exper- 
iments a duodenogastric reflux was only rarely ob- 
served, a release of somatostatin-14 caused by a 
direct action of bile on gastric D cells seems un- 
likely. As SLI is also released by vagal stimulation 
(17,47), neural mechanisms may be responsible for 
the bile-induced release of somatostatin-14 from the 
pancreas. In this context, it is noteworthy that 
cholinergic mechanisms are activated by bile as in- 
dicated by bile-induced PP release (1) and by Forell 
(22). Gastroenteropancreatic peptides (e.g., secre- 
tin) are involved in the mediation of the bile effect 
on the exocrine pancreas (1). Therefore, additional 
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release of somatostatin secondary to these peptides 
(48) warrants discussion. 
After the highest dose of bile, the increase of 
plasma SLI concentrations was comparable to that 
found postprandially (15,17). Moreover, postpran- 
dial plasma levels of SLI are capable of inhibiting 
exocrine pancreatic secretion ( 1 9 ,  especially with 
respect to the ecbolic output (49). Therefore, the 
release of somatostatin may-together with that of 
PP (1)-be responsible for the lack of further in- 
crease of enzyme secretion after the highest doses 
of bile and TDC, respectively. 
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